Laing NG. Genetics of neuromuscular disorders. Crit Rev Clin Lab Sci. 2012;49:33–48.
Carey IM, Banchoff E, Nirmalananthan N, Harris T, DeWilde S, Chaudhry UAR, et al. Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: a retrospective study using primary care data. PLoS ONE. 2021. https://doi.org/10.1371/journal.pone.0261983.
Müller KI, Ghelue MV, Lund I, Jonsrud C, Arntzen KA. The prevalence of hereditary neuromuscular disorders in Northern Norway. Brain Behav. 2021;11: e01948.
Lek M, MacArthur D. The challenge of next generation sequencing in the context of neuromuscular diseases. J Neuromuscul Dis. 2014;1:135–49.
Koczwara KE, Lake NJ, DeSimone AM, Lek M. Neuromuscular disorders: finding the missing genetic diagnoses. Trends Genet. 2022;38:956–71.
Benarroch L, Bonne G, Rivier F, Hamroun D. The 2024 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord. 2024;34:126–70.
Estévez-Arias B, Matalonga L, Yubero D, Polavarapu K, Codina A, Ortez C, et al. Phenotype-driven genomics enhance diagnosis in children with unresolved neuromuscular diseases. Eur J Hum Genet. 2024. https://doi.org/10.1038/s41431-024-01699-4.
Mary P, Servais L, Vialle R. Neuromuscular diseases: Diagnosis and management. Orthop Traumatol Surg Res. 2018;104:S89-95.
Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. J Peripher Nerv Syst. 2021;26:242–68.
Aragon-Gawinska K, Mouraux C, Dangouloff T, Servais L. Spinal muscular atrophy treatment in patients identified by newborn screening-a systematic review. Genes (Basel). 2023;14:1377.
Nicolau S, Milone M, Liewluck T. Guidelines for genetic testing of muscle and neuromuscular junction disorders. Muscle Nerve. 2021;64:255–69.
Rosenberg A, Tian C, He H, Ulm E, Collins Ruff K, Nagaraj CB. An evaluation of clinical presentation and genetic testing approaches for patients with neuromuscular disorders. Am J Med Genet A. 2023;191:2679–92.
Nicolau S, Liewluck T, Tracy JA, Laughlin RS, Milone M. Congenital myopathies in the adult neuromuscular clinic: Diagnostic challenges and pitfalls. Neurol Genet. 2019;5: e341.
Sivera Mascaró R, García Sobrino T, Horga Hernández A, Pelayo Negro AL, Alonso Jiménez A, Antelo Pose A, et al. Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease. Neurología (English Edition). 2024;40(3):290–305.
Vill K, Blaschek A, Gläser D, Kuhn M, Haack T, Alhaddad B, et al. Early-onset myopathies: clinical findings, prevalence of subgroups and diagnostic approach in a single neuromuscular referral center in Germany. J Neuromuscul Dis. 2017;4:315–25.
Cohen E, Bonne G, Rivier F, Hamroun D. The 2022 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord. 2021;31:1313–57.
Lange LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, Ebrahimi-Fakhari D, Gabbert C, et al. Nomenclature of genetic movement disorders: recommendations of the International Parkinson and Movement Disorder Society Task Force – an update. Mov Disord. 2022;37:905–35.
Boemer F, Caberg JH, Beckers P, Dideberg V, di Fiore S, Bours V, et al. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Sci Rep. 2021. https://doi.org/10.1038/s41598-021-99496-2.
Deenen JCW, Horlings CGC, Verschuuren JJGM, Verbeek ALM, Van Engelen BGM. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015;2:73–85.
Magda P, Latov N, Brannagan TH, Weimer LH, Chin RL, Sander HW. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2003;60:1755–9.
Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132:3175–86.
Farhad K, Traub R, Ruzhansky KM, Brannagan TH. Causes of neuropathy in patients referred as “idiopathic neuropathy.” Muscle Nerve. 2016;53:856–61.
Currò R, Salvalaggio A, Tozza S, Gemelli C, Dominik N, Galassi Deforie V, et al. RFC1 expansions are a common cause of idiopathic sensory neuropathy. Brain. 2021;144:1542–50.
Pipis M, Rossor AM, Laura M, Reilly MM. Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges. Nat Rev Neurol. 2019;15:644–56.
Gess B, Jeibmann A, Schirmacher A, Kleffner I, Schilling M, Young P. Report of a novel mutation in the PMP22 gene causing an axonal neuropathy. Muscle Nerve. 2011;43:605–9.
Bansagi B, Griffin H, Whittaker RG, Antoniadi T, Evangelista T, Miller J, et al. Genetic heterogeneity of motor neuropathies. Neurology. 2017;88:1226–34.
Lefter S, Hardiman O, Ryan AM. Methodology and design of a national epidemiological study on adult neuromuscular disease. Neuroepidemiology. 2014;43:123–30.
Megarbane A, Bizzari S, Deepthi A, Sabbagh S, Mansour H, Chouery E, et al. A 20-year clinical and genetic neuromuscular cohort analysis in Lebanon: an international effort. J Neuromuscul Dis. 2022;9:193–210.
Thongsing A, Likasitwattanakula S, Netsuwan T, Sanmaneechai O. Pediatric neuromuscular diseases prevalence in Siriraj Hospital, Thailand’s largest tertiary referral hospital. Siriraj Med J. 2020;72:125–31.
Vanherpe P, Fieuws S, D’Hondt A, Bleyenheuft C, Demaerel P, De Bleecker J, et al. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures. Orphanet J Rare Dis. 2020. https://doi.org/10.1186/s13023-020-01353-4.
Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol. 2022;21:814–29.
Fratter C, Dalgleish R, Allen SK, Santos R, Abbs S, Tuffery-Giraud S, et al. EMQN best practice guidelines for genetic testing in dystrophinopathies. Eur J Human Genet. 2020;28:1141–59.
Giardina E, Camaño P, Burton-Jones S, Ravenscroft G, Henning F, Magdinier F, et al. Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: update of the 2012 guidelines. Clin Genet. 2024;106:13–26.
Labeit S, Kolmerer B. Titins: giant proteins in charge of muscle ultrastructure and elasticity. Science. 1979;1995(270):293–6.
Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 1988;53:219–28.
Savarese M, Maggi L, Vihola A, Jonson PH, Tasca G, Ruggiero L, et al. Interpreting genetic variants in Titin in patients with muscle disorders. JAMA Neurol. 2018;75(5):557–65.
Bardakov SN, Tsargush VA, Carlier PG, Nikitin SS, Kurbatov SA, Titova AA, et al. Magnetic resonance imaging pattern variability in dysferlinopathy. Acta Myol. 2021;40:158–71.
Al-Dewik N, Mohd H, Al-Mureikhi M, Ali R, Al-Mesaifri F, Mahmoud L, et al. Clinical exome sequencing in 509 Middle Eastern families with suspected Mendelian diseases: the Qatari experience. Am J Med Genet A. 2019;179:927–35.
Mavraki E, Labrum R, Sergeant K, Alston CL, Woodward C, Smith C, et al. Genetic testing for mitochondrial disease: the United Kingdom best practice guidelines. Eur J Hum Genet. 2023;31:148–63.
Toscano A, Rodolico C, Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med. 2019;7:284–284.
Lace B, Micule I, Kenina V, Setlere S, Strautmanis J, Kazaine I, et al. Overview of neuromuscular disorder molecular diagnostic experience for the population of Latvia. Neurol Genet. 2022;8: e685.
Zerres K, Schöneborn SR. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518–23.
Chiò A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020. https://doi.org/10.1016/j.neuropharm.2020.107986.
Boemer F, Caberg JH, Dideberg V, Dardenne D, Bours V, Hiligsmann M, et al. Newborn screening for SMA in Southern Belgium. Neuromuscul Disord. 2019;29:343–9.
Cairns LM, Rankin J, Hamad A, Cooper N, Merrifield K, Jain V, et al. Genetic testing in motor neuron disease and frontotemporal dementia: a 5-year multicentre evaluation. J Med Genet. 2022;59:544–8.
De Oliveira HM, Soma A, Baker MR, Turner MR, Talbot K, Williams TL. A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and republic of Ireland: implications for future planning. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24:405–13.
Wang H, Guan LP, Deng M. Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy. Front Neurosci. 2023;17: 1170996.
Plagnol V, Curtis J, Epstein M, Mok KY, Stebbings E, Grigoriadou S, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics. 2012;28:2747–54.
Greer SU, Botello J, Hongo D, Levy B, Shah P, Rabinowitz M, et al. Implementation of nanopore sequencing as a pragmatic workflow for copy number variant confirmation in the clinic. J Transl Med. 2023. https://doi.org/10.1186/s12967-023-04243-y.